High-Risk Genotypes of Human Papillomavirus at Diverse Anogenital Sites Among Chinese Women: Infection Features and Potential Correlation with Cervical Intraepithelial Neoplasia

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Jun 19

PMID 38893229

Authors

Chao Zhao

Jiahui An

Mingzhu Li

Jingran Li

Yun Zhao

Jianliu Wang

Heidi Qunhui Xie

Lihui Wei

Affiliations

Soon will be listed here.

Abstract

Background: Both cervical cancer and cervical intraepithelial neoplasia (CIN) are associated with human papillomavirus (HPV) infection at different anogenital sites, but the infection features of high-risk (HR) HPVs at these sites and their association with cervical lesions have not been well characterized. Given the limitation of cervical HPV 16/18 test in screening patients with high-grade CIN (CIN 2+), studies on whether non-16/18 HR-HPV subtype(s) have potential as additional indicator(s) to improve CIN 2+ screening are needed.

Methods: The infection of 15 HR-HPVs in vulva, anus, vagina, and cervix of 499 Chinese women was analyzed, and CIN lesion-associated HR-HPV subtypes were revealed.

Results: In addition to the well-known cervical-cancer-associated HPV 16, 52, and 58, HPV 51, 53, and 56 were also identified as high-frequency detected subtypes prevalently and consistently present at the anogenital sites studied, preferentially in multi-infection patterns. HPV 16, 52, 58, 56, and 53 were the top five prevalent subtypes in patients with CIN 2+. In addition, we found that cervical HPV 33/35/52/53/56/58 co-testing with HPV 16/18 might improve CIN 2+ screening performance.

Conclusion: This study provided a new insight into HR-HPV screening strategy based on different subtype combinations, which might be used in risk stratification clinically.

References

Zhao X, Hu S, Hu J, Wang H, Wen T, Feng Y . Tackling barriers to scale up human papillomavirus vaccination in China: progress and the way forward. Infect Dis Poverty. 2023; 12(1):86. PMC: 10512493. DOI: 10.1186/s40249-023-01136-6. View

Nahm F . Receiver operating characteristic curve: overview and practical use for clinicians. Korean J Anesthesiol. 2022; 75(1):25-36. PMC: 8831439. DOI: 10.4097/kja.21209. View

Tranberg M, Jensen J, Bech B, Andersen B . Urine collection in cervical cancer screening - analytical comparison of two HPV DNA assays. BMC Infect Dis. 2020; 20(1):926. PMC: 7716507. DOI: 10.1186/s12879-020-05663-7. View

Tong T, Su D, Yang Q, Yang K, Liu Y, Wang Q . Multiple high-risk HPV infections probably associated with a higher risk of low-grade cytological abnormalities but not with high-grade intraepithelial lesions of the cervix. World J Surg Oncol. 2024; 22(1):79. PMC: 10938671. DOI: 10.1186/s12957-024-03360-2. View

Li M, Zhao C, Zhao Y, Li J, Wang J, Luo H . The role of PAX1 methylation in predicting the pathological upgrade of cervical intraepithelial neoplasia before cold knife conization. Front Oncol. 2023; 12:1064722. PMC: 9875021. DOI: 10.3389/fonc.2022.1064722. View

Rumbold A, Tan S, Condon J, Taylor-Thomson D, Nickels M, Tabrizi S . Investigating a cluster of vulvar cancer in young women: a cross-sectional study of genital human papillomavirus prevalence. BMC Infect Dis. 2012; 12:243. PMC: 3507832. DOI: 10.1186/1471-2334-12-243. View

de Sanjose S, Alemany L, Ordi J, Tous S, Alejo M, Bigby S . Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer. 2013; 49(16):3450-61. DOI: 10.1016/j.ejca.2013.06.033. View

Rosario A, Sousa A, Marinho-Dias J, Medeiros R, Lobo C, Leca L . Impact of high-risk Human Papillomavirus genotyping in cervical disease in the Northern region of Portugal: Real-world data from regional cervical cancer screening program. J Med Virol. 2022; 95(1):e28414. DOI: 10.1002/jmv.28414. View

Roden R, Wu T . How will HPV vaccines affect cervical cancer?. Nat Rev Cancer. 2006; 6(10):753-63. PMC: 3181152. DOI: 10.1038/nrc1973. View

10.

Chen Q, Qu W, Zhao Y, Shu L, Wang Y, Chen X . The prevalence of HPV among 164,137 women in China exhibited some unique epidemiological characteristics. Infect Agent Cancer. 2023; 18(1):72. PMC: 10638728. DOI: 10.1186/s13027-023-00553-4. View

11.

Amin F, Naher Z, Shaik Syed Ali P . Molecular markers predicting the progression and prognosis of human papillomavirus-induced cervical lesions to cervical cancer. J Cancer Res Clin Oncol. 2023; 149(10):8077-8086. DOI: 10.1007/s00432-023-04710-5. View

12.

McHugh M . Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012; 22(3):276-82. PMC: 3900052. View

13.

Alemany L, Saunier M, Alvarado-Cabrero I, Quiros B, Salmeron J, Shin H . Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer. 2014; 136(1):98-107. PMC: 4270372. DOI: 10.1002/ijc.28963. View

14.

Katki H, Kinney W, Fetterman B, Lorey T, Poitras N, Cheung L . Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011; 12(7):663-72. PMC: 3272857. DOI: 10.1016/S1470-2045(11)70145-0. View

15.

Serrano B, de Sanjose S, Tous S, Quiros B, Munoz N, Bosch X . Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur J Cancer. 2015; 51(13):1732-41. DOI: 10.1016/j.ejca.2015.06.001. View

16.

Luo Q, Zeng X, Luo H, Pan L, Huang Y, Zhang H . Epidemiologic characteristics of high-risk HPV and the correlation between multiple infections and cervical lesions. BMC Infect Dis. 2023; 23(1):667. PMC: 10560423. DOI: 10.1186/s12879-023-08634-w. View

17.

Yang Z, Liu H, Song R, Lu W, Wang H, Gu S . Reduced MAGI3 level by HPV18E6 contributes to Wnt/β-catenin signaling activation and cervical cancer progression. FEBS Open Bio. 2021; 11(11):3051-3062. PMC: 8564337. DOI: 10.1002/2211-5463.13298. View

18.

Wang L, Zeng J, Liu H, Xu H, Liu Y, Luo M . HPV infection and vaginal microecological disorders in women with intrauterine adhesion: cross-sectional study in a Chinese population. BMC Infect Dis. 2023; 23(1):836. PMC: 10683081. DOI: 10.1186/s12879-023-08659-1. View

19.

Liu Y, Li Z, Yuan L, Liu F, Wu K, Xiao X . Human papillomavirus genotypic characteristics of 60,685 subjects under age-expansion vaccination of the nine-valent human papillomavirus vaccine: A cross-sectional study. J Infect Public Health. 2023; 16(7):989-995. DOI: 10.1016/j.jiph.2023.04.018. View

20.

Li T, Chen S, Li X, Wu Z, Zhao Y, Cui J . The features of high-risk human papillomavirus infection in different female genital sites and impacts on HPV-based cervical cancer screening. Virol J. 2023; 20(1):116. PMC: 10246399. DOI: 10.1186/s12985-023-02073-4. View